Qisda Corporation has continued to expand its medical footprint, achieving consolidated revenue of NT$22.3 billion (US$709 million) in the first three quarters of 2025, with the traditionally strong fourth quarter expected to push full-year revenue...
The article requires paid subscription. Subscribe Now



